July 16, 2020
NIH, Moderna’s COVID-19 vaccine headed to Phase III trial
Editor's Note
Researchers testing a COVID-19 vaccine being developed by Dr Anthony Fauci’s team at the National Institutes of Health (NIH) and Moderna Inc, reported July 14 that the vaccine was able to produce neutralizing antibodies in the 45 trial participants inoculated in March.
Moderna is scheduled to launch a late-stage trial to evaluate the vaccine in 30,000 volunteers at the end of July.
Free Daily News
- Study: Music, preoperative education reduce cardiac surgery anxiety, improve recovery
- VA exempts over 300,000 healthcare jobs from federal hiring freeze
- Report: Hospital credit ratings showed mixed progress in 2024
- Proposed tariffs threaten medical device supply chain
- Providers push back on insurance cost-cutting hurdles
- EHR-integrated clinical decision support reduces unnecessary preoperative tests
- Infection control guidelines focus on regional anesthesia, pain management
- Study links high surgeon stress, positive patient outcomes
- Researchers recommend extending colonoscopy screening interval for low-risk patients
- New wrong-site surgery prevention toolkit seeing traction in ASCs
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement